Invited Speaker 37th TROG Cancer Research Annual Scientific Meeting 2025

TROG 17.02 OUTRUN: Randomised phase II trial of Osimertinib with or without stereotactic radiosurgery for EGFR mutated NSCLC with brain metastases - Update (Cat A, Closed) (#45)

Yu Yang Soon 1
  1. National University Cancer Institute, Singapore, Singapore, SINGAPORE

Content is not available at the time of publishing.